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TURNING EVIDENCE INTO PRACTICE 
Optimising opioid substitution treatment 
Although opioid substitution treatment (OST) is the most effective intervention for heroin use 
and dependence, the medication itself, and accompanying psychosocial/recovery interventions, 
need to be optimised to give the user the best chance of recovery and sustained abstinence. 
This briefing focuses on elements that can be optimised and provides key messages to help 
achieve this. The content is drawn from authoritative guidance, published evidence and service 
provider feedback.  
What is the issue? 
While more service users are completing treatment drug-free and are showing evidence of 
sustaining their recovery, others find such change difficult. We know that various treatment 
factors can help to encourage positive change and promote recovery (such as using 
recommended ‘high’ doses of OST; providing flexible and responsive services; and engaging 
service users in psychosocial and recovery-support interventions). Older, more severely 
affected and complex users who have been in treatment for many years are likely to need 
particularly careful care planning if they are to make significant gains. 
A comprehensive recovery framework for optimising OST 
Individuals whose treatment has been optimised in line with the evidence base will have their 
care competently and regularly reviewed.1 Agreement will be reached with users on the most 
appropriate combination and intensity of pharmacological, co-morbid, psychosocial and 
recovery support interventions for their treatment and recovery goals. Care will continue to be 
optimised throughout their treatment journeys, along with personalised needs assessments and 
regular progress reviews. Treatment will be adapted where evidence shows it is not meeting 
need. It is not possible to predict exactly what support options, or their order and combination, a 
particular service user will need. Providing a menu of options, carefully discussed with users 
within a positive, flexible, therapeutic and motivational framework of care is likely to be most 
effective, including targeted incentivisation (contingency management) when appropriate. OST 
may be most effective in supporting recovery within a broad evidence-based framework of care. 
“Arbitrarily curtailing or limiting the use of OST does not achieve sustainable recovery and is 
not in the interests of people in treatment or the wider community.”2 
Prompts 
1. Is there a clear vision and framework for recovery within the local system? 
2. Is there an established process of initial and ongoing need assessments within the 
service? 
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3. Can the local system provide packages of care that allow for treatment to be adapted, 
layered and phased according to individual need and changes during a recovery 
journey? 
4. Are the competences required to deliver enhanced and intensive interventions 
available within the local system? 
5. “Are arbitrary time limits for treatment or elements of it avoided but clear and ambitious 
treatment goals set, with planned timescales for action and regular reviews?”2 
6. Is there an established process for reviewing progress that includes measuring 
improvements in severity, complexity and recovery capital?  
7. Do users receive psychosocial interventions that are delivered by competent 
keyworkers? 
8. Does the range of psychosocial and recovery support interventions effectively meet 
the needs of the local treatment population? 
Shelford Treatment and Recovery Service (STARS), North Lincolnshire 
STARS was set up in October 2012 to improve the recovery orientation of OST locally. 
Service users at STARS have their OST reviewed fortnightly – a process that is explained 
during their induction. The keyworker and an independent nurse prescriber conduct the 
reviews in collaboration with the user, and the keyworker reports on the user’s progress and 
drug test results. Medication doses are increased or decreased, depending on need, with 
psychosocial interventions added or changed in response to the user’s progress (or lack of 
it). Previously nearly all users on OST received methadone. Now treatment is tailored to the 
specific needs of the user, two in every five STARS service users receive buprenorphine or 
buprenorphine-with-naloxone. 
 
Achieving adequate opioid levels 
The recommended higher doses of OST are associated with positive treatment outcomes 
(including longer-term recovery with sustained abstinence). The recommended average 
effective doses are 60-120mg/day of methadone, and 12-16mg/day (or up to 32mg in some 
cases) of buprenorphine.3 The primary reason for prescribing ongoing OST is to stop all on-top 
heroin use (or other opioid use). Higher dose OST can also help achieve greater stability 
overall. Some users opt for lower doses of OST and it is quite appropriate to prescribe this 
given the known value of responsive and flexible provision, and given the likely benefits that will 
accrue even if there is initially only partial substitution. For those who have not stopped using 
heroin and who are less stable, safe prescribing and dispensing systems (including access to 
supervised consumption) can help limit the risk of diversion. When a user receives a OST dose 
that is adequate for them, they will generally be in a better position to make informed choices 
about their next steps for recovery, including if or when to pursue sustained abstinence. 
Prompts 
1. Is there an induction procedure that ensures users are given information about the 
medications they will receive, including the consequences of sub-optimal doses? 
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2. Does the workforce have the necessary competences to ensure this information is 
effectively communicated to users? 
3. Do initial care plans include goals for progressively increasing OST doses, until the 
service user stops using on top and/or reaches a dose of 120mg/day methadone (or 
occasionally more) or 16mg/day buprenorphine (or up to 32mg in some cases)? 
4. Do local prescribing policies and dispensing arrangements include provisions for split 
dosing for users who receive methadone but still experience low-grade withdrawal 
symptoms4 (including those on doses of more than 100mg/day)? 
5. Have medications and dosing been audited to determine what proportion of the 
treatment population is being provided an ongoing OST dose that is less than the 
recommended average range? 
6. Has the service identified any users receiving sub-optimal doses? If so, is there a plan 
to undertake a focused piece of work to optimise their treatment? 
7. Are users regularly drug tested (including those taking less than the recommended 
doses for ongoing OST) to identify those who are still using on top? Does evidence of 
ongoing use automatically lead to an appropriate focus in the keyworking or other one-
to-one reviews? 
West Essex Community Drug and Alcohol Team 
All service users starting OST at West Essex CDAT have one-to-one inductions with a 
medical professional to discuss what treatment is available, how treatment works in terms of 
recovery, users’ expectations, and any concerns they may have. The induction also covers 
the consequences of sub-optimal doses and debunks the myths users starting treatment 
often have about OST (which can be barriers for optimising doses) and harm minimisation 
(including safe practices and high-risk behaviour). 
 
A range of medications 
Optimised oral methadone and buprenorphine are the first-line pharmacological interventions 
for opioid dependence5,6 and effectively help many users to substantially reduce or stop their 
heroin use. However, a small proportion of people fails to benefit significantly from these 
medications and may instead benefit from other medications. 
Prompts 
1. Does the local system offer a range of OST medications for users who fail to benefit 
from first-line interventions and who show a clinical need for alternative medications to 
be considered? 
2. Are the necessary clinical competences and experience available in the local 
treatment system to support the availability and use of a range of medications? 
3. Is the workforce suitably knowledgeable about the evidence and guidance for OST? 
4. Do local prescribing policies support the use of a range of OST medications?  
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5. Is information available to users to enable them to make informed choices about the 
medication they may be prescribed? 
6. Are users actively encouraged to get involved in making decisions about the 
medication to be prescribed? 
 
Supervised consumption: monitoring safety and providing support 
Supervised consumption supports safer initial OST titration, as it assures continued protective 
tolerance for users and reduces the risk of them diverting their medication. When provided 
positively and confidentiality, supervision can be a source of regular and frequent support for 
users and is a way to closely monitor their day-to-day progress (as is daily collection to a lesser 
degree). UK studies have shown that users understand and value the role of supervised 
consumption7 but still consider it important to have the opportunity to move away from 
supervision as they make progress in treatment.8 
Prompts 
1. Are local protocols in place for supervised consumption and are they consistent with 
national clinical guidelines? 
2. Are the process and purposes of supervised consumption effectively communicated to 
users in a positive and supportive way? 
3. Is there local capacity to ensure that all new users are supervised during the titration 
process and can be supervised for a further three months or more?  
4. Is supervised consumption flexible enough to meet individual need, ie, shorter for 
more stable users and longer (even indefinite) for those who fail to respond (who may 
continue to pose a danger to themselves or to others)? 
5. Are clinical decisions to relax, drop or reinstate supervised consumption regularly 
reviewed and based on individual users’ present circumstances, taking into account 
their level of stability, work commitments and level of risk (especially to children)? 
6. Is supervised consumption implemented in a way that incentivises compliance (using 
contingency management principles) and offers a real opportunity to move away from 
supervision? 
Torbay Primary Care Drug Service 
Torbay’s guidelines for supervised consumption ensure sufficient capacity for OST 
medications to be dispensed daily and consumed under pharmacy supervision for all new 
users. They are informed at the outset of treatment that the decision for daily supervised 
consumption will be reviewed within three months and of the criteria that must be met if 
supervision is to be relaxed. Users are assessed on their own merits and the requirement for 
supervised consumption is relaxed in stages providing the stability criteria are met. There 
are four stages over a 12-month period: 1) daily supervised consumption, 2) daily pick up, 3) 
twice-weekly pick up, 4) weekly pick up. If there are concerns at any time, daily supervised 
consumption will be reinstated. 
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Biological testing to monitor compliance and reinforce change 
Testing biological fluids for prescribed and non-prescribed drugs can be a powerful motivator 
for users. Tests can confirm treatment compliance (eg, the user is taking medication as 
prescribed) and progress (eg, confirming abstinence), and monitor continued drug use. 
Prompts 
1. Are local protocols in place that clearly communicate to staff the role of drug testing 
during OST and how it should be implemented to support optimised treatment? 
2. Are users provided with sufficient information about the uses of drug testing, including 
how it is used to inform the treatment they receive? 
3. Are drug tests used in combination with a range of other monitoring measures to 
regularly review the user’s progress? 
4. Do tests cover a range of drugs (and alcohol), taking into account that users may 
transfer dependence from one drug to another while in treatment? 
5. Are drug tests used to corroborate and reinforce self-reported abstinence? 
6. Is a negative test result used motivationally, to support and encourage service users in 
continuing to make progress? 
7. Is a series of negative drug tests used to review, reinforce and reward treatment 
progress, with relaxation of supervised consumption where appropriate? 
8. Do positive drug tests for those on OST lead to reviews of progress and care plans, 
and to increased treatment support or enhanced safety measures where appropriate? 
 
Using contingency management to reinforce compliance 
Though the contribution of contingency management (ie, receiving valued incentives for clearly 
defined progress or goals) to longer-term recovery is not yet clear, it is based on the simple 
principle that if behaviour is reinforced it is more likely to occur again.9 Contingency 
management can be very effective in supporting improvements in treatment compliance, in 
achieving and sustaining periods of continuous abstinence, and in helping to reduce or 
eliminate the use of crack cocaine among users engaged in OST programmes. 
Prompts 
1. Are local protocols in place to support the delivery of contingency management 
interventions to improve OST optimisation and support intensified treatment? 
2. Is there local agreement on what sort of behaviour contingency management may 
target, such as drug abstinence, compliance, etc? 
3. Is there sufficient expertise in the local area to effectively deliver contingency 
management interventions? 
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4. Are contingency management interventions used to support engagement and 
stabilisation during the initial phases of treatment? 
Bridge Project, Bradford 
Following rapid titration and stabilisation, users at the Bridge Project in Bradford start an 
intense, eight-week programme that involves contingency management and supports 
engagement and stabilisation. The programme involves weekly random drug testing. Those 
who test negative for their presenting drugs receive a congratulatory letter from the service. 
Letters are personalised and contain inspirational messages. The service has found that the 
letters are important to users, who find them motivating – they like to keep them and show 
them to their family members. Staff at the service are trained in the practical and theoretical 
aspects of contingency management, including what it is (and is not), the research and 
evidence base that supports it, and the importance of consistency. Staff also have a 
contingency management protocol that provides step-by-step guidance on delivering the 
programme. 
 
Other briefings in the ‘Turning evidence into practice’ series: 
 Helping service users to access and engage with mutual aid [NTA, 2013] 
 Helping service users to engage with treatment and stay the course  [PHE, 2013] 
 Biological testing in drug and alcohol treatment [PHE, 2013] 
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